Loading clinical trials...
Loading clinical trials...
A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder
Conditions
Interventions
ALKS 5461
ALKS 5461 Placebo
Locations
35
United States
Alkermes Investigational Site
Tucson, Arizona, United States
Alkermes Investigational Site
Little Rock, Arkansas, United States
Alkermes Investigational Site
Los Alamitos, California, United States
Alkermes Investigational Site
Oceanside, California, United States
Alkermes Investigational Site
Pico Rivera, California, United States
Alkermes Investigational Site
Redlands, California, United States
Start Date
June 12, 2017
Primary Completion Date
February 26, 2020
Completion Date
March 5, 2020
Last Updated
April 8, 2021
NCT07523048
NCT07226661
NCT07115329
NCT06793397
NCT06132581
NCT07025720
Lead Sponsor
Alkermes, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions